Antitumor and Antimicrobial Activity of Some Cyclic Tetrapeptides and Tripeptides Derived from Marine Bacteria

Subrata Chakraborty 1, Dar-Fu Tai 1,*, Yi-Chun Lin 2 and Tzyy-Wen Chiou 2

1 Department of Chemistry, National Dong Hwa University, Hualien 974, Taiwan; E-Mail: cpapu2000@yahoo.com
2 Department of Life Science, National Dong Hwa University, Hualien 974, Taiwan; E-Mails: a30483@yahoo.com.tw (Y.C.L.); twchiou@mail.ndhu.edu.tw (T.W.C.)

* Author to whom correspondence should be addressed; E-Mail: dftai@mail.ndhu.edu.tw; Tel.: +886-3-863-3579; Fax: +886-3-863-3570.

Academic Editor: Peter Duggan

Received: 21 April 2015 / Accepted: 6 May 2015 / Published: 15 May 2015

Abstract: Marine derived cyclo(Gly-L-Ser-L-Pro-L-Glu) was selected as a lead to evaluate antitumor-antibiotic activity. Histidine was chosen to replace the serine residue to form cyclo(Gly-L-His-L-Pro-L-Glu). Cyclic tetrapeptides (CtetPs) were then synthesized using a solution phase method, and subjected to antitumor and antibiotic assays. The benzyl group protected CtetPs derivatives, showed better activity against antibiotic-resistant Staphylococcus aureus in the range of 60–120 μM. Benzyl group protected CtetPs 3 and 4, exhibited antitumor activity against several cell lines at a concentration of 80–108 μM. However, shortening the size of the ring to the cyclic tripeptide (CtriP) scaffold, cyclo(Gly-L-Ser-L-Pro), cyclo(Ser-L-Pro-L-Glu) and their analogues showed no antibiotic or antitumor activity. This phenomenon can be explained from their backbone structures.

Keywords: antibiotic; antitumor; cyclic tetrapeptide; cyclic tripeptide

1. Introduction

The discovery and study of antimicrobial peptides (AMPs) has greatly affected the field of drug design [1,2]. Many of these host-defense peptides (HDPs) are also anticancer peptides (ACPs) with potent abilities to inhibit the growth of a wide range of cancer cells [3–6]. Although the antimicrobial activity of peptides can now be predicted [7,8], the potency of these antimicrobial peptides is normally
not as strong as certain conventional antibiotics. Their major strengths are broad-spectrum abilities to kill multi-drug-resistant bacteria at similar concentrations, rapid bacterial activity, and low propensity for resistance [9,10].

Designing and creating orally potent constrained peptides with cell-penetrating and targeted protein interacting properties is an emerging area of drug discovery. To increase the efficacy of this kind of peptide, with cyclization, it is possible to systematically improve both the pharmacodynamics and pharmacokinetic properties [11–13]. Cell-permeable bicyclic peptides are known to gain inhibition properties [14,15]. Another strategy is to use a small, low molecular weight peptide [16,17] which lowers the minimum inhibitory concentration (MIC) as well as the cost of synthesis. Their sequence can also be altered to increase specificity and activity; or to decrease toxicity [18]. Cyclic tetrapeptides (CtetPs) are constrained by privileged secondary structures, can self-assemble, and stack up to form hollow, β-sheet-like nanotubes [19]. They have been characterized as potent and highly selective molecules in a diverse range of therapeutic areas such as the antiproliferative agent cyclo(L-Pro-L-Leu-L-Pro-L-Leu) [20], tyrosinase inhibitor cyclo(L-Pro-L-Tyr-L-Pro-L-Val) [21], and many histone deacetylase inhibitors [22–24]. The discovery of these bioactive peptides has led to further development of their antagonists or agonists. Numerous efforts have been focused on building a variety of peptidomimetics [25–27]. Recently, a new antibiotic teixobactin [28] was found to inhibit cell wall synthesis. This linear peptide linked cyclic pseudopeptide is effective against drug-resistant pathogens in a number of animal models of infection. Antibiotics of this type are likely to avoid development of resistance. These types of pseudopeptides use the conformational preferences of fused rings, stereochemistry, and strong covalent bonds to define their shape for molecular recognition [29]. Thus, rigid peptidomimetics are useful tools to construct confined nanospaces [30] for structure-activity studies in peptide-based drug discovery [8].

Antimicrobial activity of cyclo(Gly-L-Ser-L-Pro-L-Glu) against Bacillus subtilis has been reported [31]. This anionic AMP was first isolated from the Ruegeria strain of marine bacteria and found to possess moderate bactericidal activity. Its structure was elucidated based on 1D and 2D NMR data, followed by determination of absolute configuration [32,33]. Recently, the coordination of cyclo(Gly-L-Ser-L-Pro-L-Glu) with a lead ion was reported [19]. However, their antitumor activity has never been explored and their antibiotic activity against other bacteria has not been reported. Herein, several analogs based on the target cyclo(Gly-L-Ser-L-Pro-L-Glu) were synthesized. Their antibiotic and antitumor activities were then evaluated with minimal inhibitory concentrations (MICs) assay [34] and MTT assay [35].

2. Results and Discussion

The vast majority of ACPs are cationic and adopt a molecular architecture such as α-helical (α-ACPs), β-sheet (β-ACPs) or extended ACPs (E-ACPs) [3,36,37]. We focused our efforts using CtetPs as β-turn (U-ACPs) mimicry as innate defense regulators (IDRs) to explore novel antitumor activities. The difficult macrocyclizations for synthesizing hydrophobic CtetPs and their side-chain protected peptides was a challenging task [38,39]. In view of the wide array of bioactivities possessed by natural CtetPs, an efficient large-scale synthesis of pure products is required to evaluate the biological potential of promising bioactive compounds. Therefore, effort was directed toward the synthesis of an anionic CtetP 1 using a solution phase method. Since cationic AMP [40,41] is more common, the serine residue
was then replaced with histidine providing analogous derivatives. Histidine can balance the charge and exert antibiotic activity [42–44]. In addition, \textit{cyclo} (Gly-L-His-L-Pro-L-Glu) \textbf{2} must be able to cyclize from its linear precursor.

2.1. Cyclic Tetrapeptides Syntheses

Dibenzyl L-glutamate toluene sulphonate [45] was used as the starting material to synthesize the CtetPs. Scheme 1 shows linear tetrapeptide Boc-GS(OBn)PE(OBn)\textsubscript{2} \textbf{9} synthesized from Fmoc-L-proline. Enzymatic hydrolysis of the \(\alpha\)-benzyl ester on glutamate was achieved regioselectively as a key step [46]. The \(\alpha\)-carboxylic acid \textbf{10} was then activated with pentafluorophenol and cyclized with pyridine to form CtetP \textbf{3} [47]. Deprotection of the benzyl group on compound \textbf{3} completed the synthesis of CtetP \textbf{1} [19].

![Scheme 1. Synthesis of \textit{cyclo}(Gly-L-Ser-L-Pro-L-Glu). Reagents and conditions:
\(\text{(a)}\) \(p\)TSA-H\(_2\)N-Glu-(OBn)\(_2\), DCC, HOBr, TEA, DCM, 0 °C–rt, overnight; \(\text{(b)}\) (i) 20% piperidine in DCM, (ii) Boc-Ser-OH, DCC, HOBr, TEA, DCM, 0 °C–rt, overnight; \(\text{(c)}\) (i) TFA, DCM, rt, (ii) Boc-Gly-OH, DCC, HOBr, TEA, DCM, 0 °C–rt; \(\text{(d)}\) \textit{B. subtilis} protease, pH 7, H\(_2\)O, acetone, 37 °C; \(\text{(e)}\) (i) DCC, pentafluorophenol, DCM, (ii) TFA, DCM, 0 °C, (iii) pyridine, high dilution, 90 °C, 24 h; \(\text{(f)}\) H\(_2\), Pd/C, DMF.](image)
Scheme 2. Synthesis of cyclo(Gly-L-His-L-Pro-L-Glu). Reagents and conditions: (a) (i) 20% piperidine in DCM, rt, (ii) Boc-His(Bn)OH, DCC, HOBt, TEA, DCM, 0 °C–rt (b) (i) TFA/DCM(1:1) rt, (ii) Boc-Gly-OH, DCC, HOBt, TEA, DCM, 0 °C–rt; (c) B. subtilis protease (Sigma type–VIII), pH 7, H2O, acetone, 37 °C; (d) (i) DCC, pentafluorophenol, DCM, (ii) TFA/DCM(1:1), 0 °C, (iii) pyridine, high dilution, 90 °C; (e) H2, Pd(OH)2/C, DMF.

2.2. Biological Activities of CtetPs

Cyclo(Gly-L-Ser-L-Pro-L-Glu) was active against Gram-positive Bacillus subtilis [31], the synthesized compounds 1–4 were tested for antibacterial activity against Escherichia coli (E. coli), Staphylococcus aureus (S. aureus), and Pseudomonas aeruginosa (P. aer.) assay. Table 1 shows that protected CtetPs indicated moderate effects against S. aureus (minimum inhibitory concentrations (MIC) for 24 h were mostly in the range of 60 and 120 μM). These CtetPs were not active against E. coli and P. aer.

Table 1. Antibacterial and antitumor activities of cyclic tetrapeptides (CtetPs).

| R1       | R2 | E. coli | P. aer. | S. aureus | A549 | DBTRG | HepG2 | LNCaP |
|----------|----|---------|---------|-----------|------|-------|-------|-------|
| CtetP 1  | HO | H       | ---     | ---       | ---  | ---   | ---   | ---   |
| CtetP 2  | H  | H       | ---     | ---       | ---  | ---   | ---   | ---   |
| CtetP 3  | BnO| Bn      | ---     | 60        | 108  | 100   | ---   | 104   |
| CtetP 4  | Bn | Bn      | ---     | 120       | 92   | 80    | ---   | 84    |
| Tetracycline |     |         |         |           | 4.5  | 68    | 1.1   |       |
| Taxol    |     |         |         |           | 0.0026 | 0.01  | 0.0065 | 0.0018 |

*Minimal inhibitory concentrations (MICs) were defined as the lowest concentration at which no growth was detectable for 24 h. Tetracycline was used as positive control. b IC50 were recorded as the concentration (μM) at which cells were reduced 50% in 48 h. Taxol was used as positive control.*
The His-containing CtetPs, protected or not, displayed increased cytotoxic activity against antibiotic-resistant S. aureus (up to 4-fold) with respect to the Ser CtetPs. However, CtetP 3, the protected serine derivative, was the best. It is intriguing to speculate about the possible hydrophobic function on the CtetPs. The finding that benzyl protected CtetP was more effective than that without suggests that it may be particularly useful for increasing the hydrophobicity of CtetPs. Probably, the greater the hydrophobicity of the CtetPs, the greater is the antibacterial activity [48].

Surprisingly, antitumor activity against human tumor cells increased in parallel. Table 1 shows CtetP 1 and analogues which were tested for their anticancer activities towards several cancer cells using MTT assay [35]. CtetP 3 and CtetP 4 exhibited activity against three species of tumor cell, DBTRG (human brain glioblastoma multiforme), A549 (human lung adenocarcinoma epithelial), and LNCaP (human prostate carcinoma). CtetP 4 had the best results among its derivatives. These CTPs were not active against HepG2 (human hepatocellular carcinoma) cell lines. Therefore, the enhancement of peptide stability and lipophilicity improved efficacy [3–6]. Chemical modification of these compounds is promising for the development of these peptide based drugs.

2.3. Biological Activities of CtriPs

To obtain a low molecular weight peptide, contraction of the size of the ring is a relevant modification. Chemical synthesis of cyclic tripeptide (CtriP) was recently reported [49]. Such compounds with a 9-membered ring have never been examined for their antitumor-antibiotic activity. Cyclo(Gly-L-Ser-L-Pro), cyclo(L-Ser-L-Pro-L-Glu), and their analogues were tested for their antibiotic and anticancer activities towards several cancer cells using MTT assay [35]. None of the peptides were active in either antimicrobial or antitumor assays. The shorting of the peptide length by removal of Glu or Gly resulted in poor efficacy with concentration \(>200 \, \mu\text{M} \). Other protected or unprotected CtPs, such as cyclo(L-Ser(Bn)-L-Ser(Bn)-L-Ser(Bn)), cyclo(L-Ser-L-Pro-L-Ser), cyclo(Gly-L-Ser(Bn)-L-Pro), cyclo(L-Glu-L-Glu-L-Glu), and cyclo(L-Glu(OBn)-L-Glu(OBn)-L-Glu(OBn)) also showed similar results. Despite this, these compounds are promising for development as enzyme inhibitors [49], due to low cytotoxicity.

2.4. Structure and Activity Relationship of CtetPs and CtriPs

Recently, we used the angle of the C\(\alpha\) atoms for a structural description of CtriPs. The angle of the C\(\alpha\) atoms is defined as the angle between the two lines of the C\(\alpha\) atom to C\(\alpha\) atom [48]. An example of the structure of CtriP, cyclo(L-Pro-L-Pro-L-Pro) is shown in Figure 1A [50]. The angle of the C\(\alpha\) atoms is very close to 60\(^\circ\) for each angle. The C\(\alpha\) line can be considered the mainstay of the peptide backbone. As the red arrows indicate, its side chains have to follow the core’s orientation to spread out. The line of C\(\alpha\) atom to C\(\beta\) atom is critical for bioactivity [44].

CtriPs and CtetPs are strained and rigid molecules; they can bind with high affinity and specificity to protein targets. The C\(\alpha\) atom’s angle can be used to describe the different relationship of these cyclic peptides with its membrane receptors, enzymes or functional proteins. C\(\alpha\) atoms’ angles that do not match the binding site are unable to bind. Through the interaction of the C\(\alpha\) atom’s angle, these structures are complementarily placed in the binding site of protein targets. A sharp C\(\alpha\) atom’s angle may be critical
to fit in the binding domain. The pocket needs to be folded to nearly 300° to induce a binding with a CtriP (Figure 1A). This decreases the chance for CtriPs to obtain better inhibiting activity.

![Figure 1](image.png)

**Figure 1.** (A) An artifact structure of cyclo(L-Pro-L-Pro-L-Pro) [50] and (B) crystal structure of cyclo(Gly-L-Ser-L-Pro-L-Glu) [19] with their Cα lines in green. The red arrow indicates the orientation of the Cα atom to the Cβ atom line.

The crystal structure of cyclo(Gly-L-Ser-L-Pro-L-Glu) and its Cα lines are shown in Figure 1B [19]. For CtetP, the four Cα lines are not in the same plane and not a quadrangle. A CtetP could be considered a composition of two CtriPs (two triangles), but actually all their Cα atoms’ angles are larger than 60°. We suggest that larger Cα atoms’ angles are necessary for CtetPs to become active relative to the pocket size of the target protein for antibiotic or antitumor activity. Due to the direction of the Cα atom to Cβ atom line being different to CtetP, these CtriPs are less likely to affect the proteins. This is probably the reason why CtriPs are not effective as antibiotic or antitumoral reagent.

Due to their backbone differences, CtriPs, with suitable functional groups, may facilitate the interaction with a particular protein that is not applicable to CtetPs [49], and *vice versa*. The overall clinical outcomes of the Cα atom’s angle still need to be optimized by structure modifications for a thorough investigation.

### 3. Experimental Section

#### 3.1. General

All reagents were commercially available (Aldrich or Merck) and used as supplied. Solvents were dried by standard procedures. The NMR spectra were recorded on a Bruker DRX 400, (1H at 400.13 MHz, 13C at 100.03 MHz) spectrometers (Bruker Daltonics, Bremen, Germany). MALDI TOF was performed on a Bruker Autoflex MALDI-TOF mass spectrometer (Bruker Daltonics, Bremen, Germany). High-resolution electrospray ionization mass spectrometry (ESI-MS) was performed on a Shimadzu LCMS-IT-TOF mass spectrometer (Shimadzu, Kyoto, Japan). Infrared spectra were recorded...
on a Perkin Elmer Spectrum one FT-IR spectrometer (Perkin Elmer, Shelton, CT, USA) using KBr pellets (4000–400 cm$^{-1}$) (Fluka, Milwaukee, WI, USA).

3.2. Bacterial Strains and Culture Conditions

*Staphylococcus aureus* ATCC 25923 and *Escherichia coli* ATCC 25922 were obtained from Bioresource Collection and Research Center (Hsinchu, Taiwan). *Staphylococcus aureus* was grown in Tryptic soy broth (TSB) at 37 °C. *Pseudomonas aeruginosa* and *Escherichia coli* were grown in Luria-Bertani (LB) broth at 37 °C.

3.3. Chemicals

Tetracycline and taxol was purchased from Sigma Aldrich (St. Louis, MO, USA). Agar and bacterial growth media such as Tryptic soy broth (TSB) and Luria-Bertani (LB) broth were purchased from Merck (Pvt. Ltd., Selangor, Malaysia).

3.3.1. Fmoc-L-prolyl-L-glutamyl Dibenzyl Ester (5)

To a solution of triethylamine (3 g, 29.65 mmol) in dichloromethane (20 mL) in a 50 mL round bottom flask dibenzyl L-glutamyl p-toluenesulphonate (8.88 g, 17.79 mmol) was added at 0 °C and stirred for one hour. Then, Fmoc-L-proline (4 g, 11.86 mmol), DCC (dicyclohexylcarbodiimide) (2447 mg, 11.86 mmol) and HOBt (hydroxybenzotriazole) (1601 mg, 11.86 mmol) were added to the reaction mixture and stirred for 2 h at 0 °C and then 17 h at room temperature (rt). The resultant white mixture was filtered to remove 1,3-dicyclohexylurea (DCU). The filtrate was evaporated and the residue was dissolved in ethyl acetate. The resultant organic layer was washed with 5% aq. citric acid solution, followed by water, and then with 5% sodium bicarbonate solution followed by water. The organic layer was dried over Na$_2$SO$_4$. The mixture was purified by column chromatography using hexane/ethyl acetate (70:30) as eluent to obtain compound 5 as a white solid (6 g, 78%).

$^1$H NMR: (CDCl$_3$, 400 MHz) 1.88–1.99 (m, 4H); 2.25–2.40 (m, 4H); 3.46–3.56 (m, 2H); 4.24–4.34 (m, 3H); 4.41–4.46 (m, 2H); 4.61–4.69 (m, 1H); 5.04–5.17 (m, 4H); 7.30–7.39 (m, 14H); 7.59 (s, 2H); 7.75–7.77 (d, 2H, $J$ = 7.16 Hz). $^{13}$C NMR: (CDCl$_3$, 100 MHz) 27.2, 28.5, 301, 34.0, 47.1, 47.3, 51.8, 60.4, 66.5, 67.3, 67.7, 120.0, 125.1, 125.2, 127.1, 127.7, 128.2, 128.3, 128.5, 128.6, 135.3, 135.8, 143.8, 144.0, 171.4, 171.7, 172.5.

3.3.2. L-Prolyl-L-glutamyl Dibenzyl Ester (6)

To a solution of Fmoc-L-prolyl-L-glutamyl dibenzyl ester (6 g, 9.28 mmol) in a round bottom flask a solution of 20% piperidine in dichloromethane (20 mL) was added. The reaction mixture was stirred for 2 h, concentrated, and purified by column chromatography using hexane/ethyl acetate (97:3) as eluent to obtain compound 6 as a pale yellow liquid (3.7 g, 94%).

$^1$H NMR: (CDCl$_3$, 400 MHz) 1.65–1.70 (m, 4H); 1.85–1.88 (m, 1H); 2.00–2.10 (m, 2H); 2.29–2.41 (m, 3H); 2.87–2.99 (m, 2H); 3.69–3.73 (m, 1H); 4.62–4.64 (m, 1H); 5.00–5.14 (m, 4H);
7.32 (s, 10H); 8.13–8.15 (d, 1H, J = 8.48 Hz). $^{13}$C NMR: (CDCl$_3$, 100 MHz) 26.2, 27.6, 30.3, 30.9, 47.3, 51.1, 60.5, 66.5, 67.2, 128.2, 128.3, 128.4, 128.6, 128.6, 135.3, 135.8, 171.7, 172.3, 172.3, 175.4.

3.3.3 Boc-L-seryl(OBn)-L-prolyl-L-glutamate Dibenzyl Ester (7)

To a solution of triethylamine (1906 mg, 18.84 mmol) in dichloromethane (20 mL) in a round bottom flask compound 6 (4 g, 9.42 mmol) was added at 0 °C and stirred for 5 min. Then Boc-L-serine-OBn (2782 mg, 9.42 mmol), DCC (1944 mg, 9.42 mmol) and HOBt (1272 mg, 9.42 mmol) were added. The reaction mixture was stirred for 2 h at 0 °C and 17 h at room temperature. The resultant white mixture was filtered to remove 1,3-dicyclohexylurea. The filtrate was dried and the residue was dissolved in ethyl acetate. The organic layer was washed successively with 5% aq. citric acid solution, water, 5% aq. NaHCO$_3$ solution, and water. The combined organic solvent was dried over Na$_2$SO$_4$ and concentrated on a rotary evaporator. The mixture was purified by column chromatography using ethyl acetate and hexane (70:30) as eluent to obtain the pure product (Yield—76%).

$^1$H NMR: (CDCl$_3$, 400 MHz) 1.43 (s, 9H); 1.93–2.26 (m, 8H); 3.58–3.67 (m, 4H); 4.40–4.46 (m, 3H); 4.49–4.61 (m, 2H); 5.05–5.12 (m, 4H); 7.16–7.35 (m, 15H). $^{13}$C NMR: (CDCl$_3$, 100 MHz) 24.80, 26.96, 27.99, 28.34, 30.05, 47.68, 51.46, 51.54, 60.21, 66.35, 67.14, 71.01, 73.24, 79.99, 127.22, 127.78, 128.26, 128.36, 128.41, 128.47, 128.55, 128.57, 135.37, 135.83, 135.56, 155.17, 170.67, 170.86, 171.16, 172.29.

3.3.4 L-Seryl(OBn)-L-prolyl-L-glutamate Dibenzyl Ester (8)

To a round bottom flask containing compound 7 (5 mg, 7.12 mmol) 10 mL of TFA (Trifluoroacetic acid)/DCM (1:1) was added and stirred for 1 h at rt. The organic solvents were evaporated and the resultant mixture was purified by column chromatography using DCM/MeOH (97:3) as eluent to obtain compound 8 (Yield—95%).

$^1$H NMR: (CDCl$_3$, 400 MHz) 1.85–1.98 (m, 6H); 2.28–2.32 (m, 2H); 3.44–3.58 (m, 2H); 3.75–3.86 (m, 2H); 4.41–4.54 (m, 5H); 5.00–5.12 (m, 4H); 7.19–7.44 (m, 15H); 7.44–7.46 (d, 1H, J = 7.56 Hz). $^{13}$C NMR: (CDCl$_3$, 100 MHz) 24.81, 26.59, 28.50, 30.29, 47.64, 51.86, 52.29, 60.65, 66.57, 66.97, 67.25, 73.52, 127.73, 128.15, 128.25, 128.55, 135.25, 135.66, 136.82, 132.20, 171.01, 171.45, 172.98.

3.3.5 Boc-glycyl-L-seryl(OBn)-L-prolyl-L-glutamate Dibenzyl Ester (9)

To a solution of compound 8 (2.9 mg, 4.82 mmol) and triethylamine (975 mg, 9.64 mmol) in dichloromethane (15 mL) in a round bottom flask at 0 °C Boc-glycine-OH (845 mg, 4.82 mmol), DCC (995 mg, 4.82 mmol) and HOBt (651 mg, 4.82 mmol) were added. The reaction mixture was stirred for 2 h at 0 °C and 17 h at rt. The resultant white mixture was filtered to remove 1,3-dicyclohexylurea. The filtrate was dried and the residue was dissolved in ethyl acetate. The organic layer was washed successively with 5% aq. citric acid solution, water, 5% aq. NaHCO$_3$ solution, and water. The organic layer was dried over Na$_2$SO$_4$ and concentrated. The resultant mixture was purified by column chromatography using DCM/MeOH (97:3) as eluent to obtain compound 9 (Yield—75%).
**1H NMR:** (CDCl₃, 400 MHz) 1.43 (s, 9H); 1.85–1.98 (m, 6H); 2.28–2.32 (m, 2H); 3.44–3.58 (m, 2H); 3.75–3.86 (m, 2H); 4.41–4.54 (m, 5H); 5.00–5.12 (m, 4H); 7.19–7.44 (m, 15H); 7.44–7.46 (d, 1H, J = 7.56 Hz). **13C NMR:** (CDCl₃, 100 MHz) 24.74, 27.03, 28.31, 30.10, 44.01, 47.78, 50.35, 51.49, 60.28, 66.35, 67.13, 70.28, 73.28, 73.41, 80.22, 127.33, 127.81, 128.25, 128.27, 128.32, 128.42, 128.48, 128.56, 128.58, 135.37, 135.82, 137.50, 155.91, 169.12, 169.87, 170.96, 171.12, 172.24.

3.3.6. Boc-glycyl-L-seryl(OBn)-L-prolyl-L-glutamic acid-α-COOH-γ-OBn (**10**)

To a solution of *B. subtilis* protease (Sigma type—Ill) (2 mg) in 0.1 M phosphate buffer (pH = 7) (3.2 mL) a solution of compound **9** (620 mg, 0.82 mmol) in 0.8 mL acetone at rt was added drop by drop. The reaction mixture was stirred at 35 °C overnight. Then the solution was basified to pH 8 to remove unchanged ester by ethyl acetate. The aqueous layer was acidified to pH 2 and centrifuged to remove enzyme. The resultant mixture was extracted with ethyl acetate and dried over Na₂SO₄. The organic solvent was evaporated to obtain compound **10** (Yield—85%).

**1H NMR:** (CDCl₃, 400 MHz) 1.40 (s, 9H); 1.69–1.72 (m, 1H); 1.90–2.09 (m, 4H); 2.16–2.27 (m, 3H); 3.61–3.68 (m, 4H); 3.80–3.82 (m, 2H); 4.42–4.58 (m, 4H); 5.03–5.15 (m, 5H); 7.16–7.32 (m, 15H). **13C NMR:** (CDCl₃, 100 MHz) 24.78, 26.93, 28.32, 30.40, 43.72, 47.28, 48.05, 50.39, 51.66, 60.77, 66.46, 69.90, 73.35, 80.10, 127.44, 127.99, 128.27, 128.48, 128.57, 135.74, 137.25, 156.11, 169.75, 170.63, 171.39, 172.60, 172.83.

3.3.7. Cyclo(glycyl-L-seryl(OBn)-L-prolyl-L-glutamyl(OBn)) (**3**)

To a solution of compound **10** (200 mg, 0.29 mmol) in dichloromethane (2 mL) at 0 °C pentafluorophenol (59 mg, 0.32 mmol) and DCC (60 mg, 0.29 mmol) were added and then stirred for 1 h at 0 °C and 22 h at rt. The organic solvent was evaporated and the residue was dissolved in ethyl acetate and filtered to remove 1,3-dicyclohexylurea. The filtrate was washed with 5% aq. NaHCO₃ solution, followed by water. The organic layer was dried over Na₂SO₄ to obtain pentafluorophenolic ester. The white fluffy compound was used for the next reaction without further purification.

To a solution of Boc-glycyl-L-seryl(OBn)-L-prolyl-L-glutamic acid-γ-OBn-α-pentafluorophenolic ester (215 mg, 0.26 mmol) in dichloromethane (2 mL), TFA (2 mL) was added at 0 °C and stirred for 1 h at 0 °C. The organic solvents were evaporated; triturating with ether followed by decanting to remove free pentafluorophenol. The resultant residue was dried under vacuum, which was used directly in the ensuing cyclization.

To a solution of pyridine (150 mL) in a 300 mL round bottom flask at 90 °C a solution of glycyl-L-seryl(OBn)-L-prolyl-L-glutamic acid-γ-OBn-α-pentafluorophenolic ester (200 mg, 0.272 mmol) in dried 1,4-dioxane (10 mL) was added drop wise with efficient stirring. Addition was completed after 6 h. After stirring for 24 h, the solvent was distilled off. The resultant residue was treated several times with ether and finally methanol was added to precipitate the product. The precipitate was washed with 1 N HCl, water and finally with methanol and dried in vacuum to obtain compound **3** as a white solid (overall Yield—60%).

**1H NMR:** (CD₃OD & CDCl₃, 400 MHz) 1.62–1.76 (m, 3H); 1.98–2.03 (m, 3H); 2.15–2.26 (m, 2H); 3.25–3.9 (m, 2H); 3.49–3.69 (m, 2H); 3.75–3.90 (m, 2H); 4.18–4.20 (d, 1H, J = 8 Hz); 4.27 (d, 2H, J = 8 Hz).
3.3.8. Cyclo(glycyl-L-seryl-L-prolyl-L-glutamyl) (1)

To a solution of compound 3 (100 mg) in DMF (5 mL), 10% palladium on carbon (10 mg) was added under nitrogen. The vessel was purged three times with nitrogen and three times with hydrogen and the mixture was then stirred for 6 h under hydrogen at atmospheric pressure. The catalyst was removed by filtration and the filtrate was evaporated to obtain 1 as a white solid (Yield—95%).

$^1$H NMR: (D$_2$O, 400 MHz) 1.60–1.89 (m, 3H); 1.93–2.17 (m, 3H); 2.20–2.38 (m, 2H); 3.36–3.54 (m, 2H); 3.57–3.65 (m, 1H); 3.77–3.82 (m, 1H); 3.86–3.97 (m, 2H); 4.08–4.10 (d, 1H, $J = 8$ Hz); 4.35–4.37 (d, 1H, $J = 8$ Hz); 4.80–4.82 (m, 1H).

IR (cm$^{-1}$): 3459, 3333, 3294, 3236, 3066, 2990, 2961, 1718, 1663, 1646, 1615, 1545, 1444, 1380, 1285, 1242, 1222, 1161, 1138, 1108, 1056, 1042, 978, 925, 875, 776, 758, 679, 605, 583, 482.

MALDI-TOF: $m/z$ 371.35 $[M + H]^+$, ESI-MS: $[M - H]^{-}$ calculated $m/z$ 369.1488, obtained $m/z$ 369.1426.

3.3.9. Boc-L-histidinyl(Bn)-L-prolyl-L-glutamyl Dibenzyl Ester (11)

To a solution of triethylamine (1906 mg, 18.84 mmol) in dichloromethane (20 mL) in a round bottom flask, Boc-L-histidine(Bn) (3255 mg, 9.42 mmol), DCC (1944 mg, 9.42 mmol) and HOBt (1272 mg, 9.42 mmol) were added at 0 °C. Then L-proline-L-glutamyl dibenzyl ester 6 (4 g, 9.42 mmol) was added. The reaction mixture was stirred for 2 h at 0 °C and 17 h at rt. The resultant white mixture was filtered to remove 1,3-dicyclohexylurea. The filtrate was dried and the residue was dissolved in ethyl acetate. The organic layer was washed successively with 5% aq. citric acid solution, water, 5% aq. NaHCO$_3$ solution, and water. The combined organic layer was dried over Na$_2$SO$_4$ and purified by column chromatography using DCM/MeOH (97:3) as eluent to obtain compound 11 as a white solid (5.4 g, 76%).

$^1$H NMR: (CDCl$_3$, 400 MHz) 1.41 (s, 9H); 1.68–1.74 (m, 2H); 1.99–2.10 (m, 2H); 2.20–2.52 (m, 4H); 2.86–2.88 (d, 2H, $J = 8$ Hz); 3.35–3.41 (m, 1H); 4.43–4.51 (m, 2H); 4.58–4.60 (m, 1H); 4.93 (s, 2H); 4.95–5.07 (m, 2H); 5.13 (q, 2H); 5.51–5.53 (d, 2H, $J = 7.96$ Hz); 6.72 (s, 1H); 7.09–7.11 (m, 2H); 7.28–7.35 (m, 15H); 9.34–9.36 (d, 2H, $J = 8$ Hz). $^{13}$C NMR: (CDCl$_3$, 100 MHz) 24.7, 26.0, 28.4, 29.0, 30.5, 32.2, 47.2, 50.9, 51.8, 52.7, 60.8, 66.2, 67.0, 79.6, 117.6, 127.3, 128.1, 128.2, 128.3, 128.4, 128.5, 128.5, 129.1, 136.0, 136.9, 137.8, 155.1, 171.3, 171.4, 171.8, 172.9.

3.3.10. L-Histidinyl(Bn)-L-prolyl-L-glutamyl Dibenzyl Ester (12)

To a round bottom flask containing Boc-L-histidinyl(Bn)-L-prolyl-L-glutamyl dibenzyl ester 11 (5.4 g, 7.19 mmol), 10 mL of TFA/DCM (1:1) was added and stirred for 1 h at rt. The organic solvents were evaporated and the resultant mixture was purified by column chromatography using DCM/MeOH (97:3) as eluent to obtain compound 12 as a pale yellow liquid (4.3 g, 93%).

$^1$H NMR: (CDCl$_3$, 400 MHz) 1.84–1.86 (m, 3H); 2.05–2.25 (m, 3H); 2.42 (t, 2H, $J = 7.44$ Hz); 3.15–3.56 (m, 3H); 3.57–3.60 (m, 1H); 4.50–4.51 (m, 3H); 5.00–5.12 (m, 4H); 5.00 (s, 2H); 5.02–5.12 (m, 4H); 7.21–7.34 (m, 15H); 8.04 (s, 1H); 8.56–8.58 (d, 1H, $J = 6.12$ Hz). $^{13}$C NMR: (CDCl$_3$,
3.3.11. Boc-glycyl-L-histidinyl(Bn)-L-prolyl-L-glutamyl Dibenzyl Ester (13)

To a solution of L-histidinyl(Bn)-L-prolyl-L-glutamyl dibenzyl ester 12 (4.3 g, 6.6 mmol) and triethylamine (1336 mg, 13.3 mmol) in dichloromethane (20 mL) in a round bottom flask, Boc-glycine (1156 mg, 6.6 mmol), DCC (1362 mg, 6.6 mmol) and HOBt (891 mg, 6.6 mmol) were added at 0 °C. The reaction mixture was stirred for 2 h at 0 °C and 17 h at rt. The resultant white mixture was filtered to remove 1,3-dicyclohexylurea. The filtrate was evaporated and the residue was dissolved in ethyl acetate. The organic layer was washed successively with 5% aq. citric acid solution, water, 5% aq. NaHCO₃ solution and water. The organic layer was dried over Na₂SO₄ and concentrated. The resultant mixture was purified by column chromatography using DCM/MeOH (97:3) as eluent to obtain compound 13 as a white solid (4.4 g, 83%).

1H NMR: (CDCl₃, 400 MHz) 1.42 (s, 9H); 1.66–1.76 (m, 2H); 1.97–2.08 (m, 2H); 2.16–3.49 (m, 4H); 2.84–2.98 (m, 3H); 3.44 (q, 1H); 3.77–3.78 (d, 2H, J = 4.96 Hz); 4.48 (q, 1H); 4.56 (dd, 1H, J = 2.76 Hz, J = 8.44 Hz); 4.73–4.78 (m, 1H); 4.92 (s, 2H); 4.95–5.12 (m, 4H); 5.23 (s, 1H); 6.73 (s, 1H); 7.09–7.11 (m, 11H); 7.23–7.34 (m, 15H); 9.24–9.26 (d, 1H, J = 7.48 Hz). 13C NMR: (CDCl₃, 100 MHz) 24.6, 26.1, 28.3, 29.1, 30.5, 31.5, 44.0, 47.4, 50.9, 51.5, 51.8, 60.8, 66.2, 66.9, 80.1, 117.8, 127.4, 128.1, 128.2, 128.4, 128.5, 128.5, 129.0, 135.7, 135.8, 136.0, 136.9, 137.4, 155.9, 168.7, 170.8, 171.4, 171.8, 172.8.

3.3.12. Boc-glycyl-L-histidinyl(Bn)-L-prolyl-L-glutamic acid-γ(OBn) (14)

To a solution of B. subtilis protease (Sigma type—VIII) (50 mg) in 32 mL of 0.1 M, pH 7 phosphate buffer, a solution of Boc-glycyl-L-histidinyl(Bn)-L-prolyl-L-glutamyl dibenzyl ester 13 (4.4 g, 5.44 mmol) in acetone (8 mL) was added drop by drop. The reaction mixture was stirred at 35 °C overnight. Then the solution was basified to pH 8 to remove unchanged ester with ethyl acetate. The aqueous layer was acidified to pH 2 and centrifuged to remove enzyme. The resultant mixture was extracted with ethyl acetate and dried over Na₂SO₄ and concentrated. The resultant mixture was purified by column chromatography using DCM/MeOH (97:3) as eluent to obtain compound 14 as a white solid (3.36 g, 86%).

1H NMR: (CD₃OD, 400 MHz) 1.42 (s, 9H); 1.90–2.01 (m, 4H); 2.20–2.29 (m, 2H); 2.47–2.55 (m, 2H); 2.98 (dd, 1H, J = 5.6 Hz, J = 15.08 Hz); 3.17 (dd, 1H, J = 6.8 Hz, J = 15.04 Hz); 3.45–3.52 (m, 1H); 3.62 (s, 2H); 4.44 (q, 1H); 4.50 (q, 1H); 4.93 (s, 1H); 5.09 (q, 2H); 5.34 (s, 2H); 7.23–7.34 (m, 15H); 7.40 (s, 1H); 8.88 (s, 1H). 13C NMR: (CD₃OD, 100 MHz) 24.6, 26.4, 26.6, 27.3, 29.3, 29.9, 43.0, 50.0, 51.5, 52.5, 60.2, 63.8, 66.0, 79.4, 110.0, 117.2, 120.8, 127.0, 127.8, 128.0, 128.2, 128.3, 129.0, 129.0, 134.0, 134.5, 136.1, 141.3, 168.6, 170.7, 172.8, 173.1, 173.4.

3.3.13. Cyclo(glycyl-L-histidinyl(Bn)-L-prolyl-L-glutamyl(OBn) (4)

A similar procedure as for the synthesis of compound 3 was applied to obtain compound 4 as a white solid with an overall yield of 52%.
\[1H \text{NMR: (CD}_3\text{OD & CDCl}_3, 400 MHz) 143–1.63 (m, 3H); 1.92 (s, 2H); 2.02–2.30 (m, 3H); 2.75–2.89 (m, 1H); 2.96–2.99 (m, 3H); 7.14–7.26 (m, 10H); 8.49 (s, 1H). 13C \text{NMR: (CD}_3\text{OD & CDCl}_3, 100 MHz) 25.4, 25.9, 30.3, 33.6, 35.8, 49.3, 51.5, 51.6, 56.7, 56.9, 65.6, 70.3, 122.5, 124.2, 132.0, 132.1, 132.2, 132.3, 132.4, 132.3, 133.5, 137.0, 139.7, 173.4, 174.3, 176.1, 176.7, 178.3. MALDI-TOF: [M + H]+ calculated m/z 601.277, obtained m/z 601.383. 3.3.14. \text{Cyclo(glycyl-L-histidinyl-L-prolyl-L-glutamyl)} (2) \]

\text{Cyclo(glycyl-L-histidinyl(Bn)-L-prolyl-L-glutamyl(OBn)} 4 (100 mg, 0.17 mmol) was dissolved in 5 mL of DMF and 10% palladium hydroxide on carbon was added under nitrogen. The vessel was purged three times with nitrogen and then the bottle was shaken at 50 lbs per sq inch hydrogen pressure in a Parr shaker for 8 h. The catalyst was removed by filtration and the filtrate was evaporated to obtain compound 2 as a white powder (77 mg, 95%) \([\alpha]^{21}_D = -117.75 \text{ (C = 0.1, H}_2\text{O).} \]

\[1H \text{NMR: (D}_2\text{O, 400 MHz) 1.56–2.02 (m, 5H); 2.16 (s, 3H); 2.83–2.93 (m, 1H); 3.10–3.20 (m, 1H); 3.39–3.58 (m, 2H); 3.63–3.75 (m, 2H); 3.80–3.95 (m, 2H); 4.08 (dd, 1H, \text{J} = 8.56 \text{ Hz, J} = 40.16 \text{ Hz); 4.88–4.98 (m, 1H); 7.14 (s, 1H); 8.44 (s,1H). 13C \text{NMR: (D}_2\text{O, 100 MHz) 21.3, 24.2, 26.0, 30.8, 31.5, 46.0, 48.0, 50.3, 51.8, 59.5, 117.4, 129.0, 133.0, 168.8, 170.6, 171.1, 173.8, 175.6. IR (cm}^{-1}) \): 3272.12, 1668.93, 1541.19, 1443.98, 1346.04, 1205.54, 1135.58, 981.93, 838.79, 799.63, 749.84, 722.56, 670.75, 629.16, 604.80, 477.38. MALDI-TOF: [M + H]+ calculated m/z 421.183, obtained m/z 421.296. HRMS (ESI): [M + H]+ calculated: m/z 421.1830, obtained: m/z 421.1841. 3.4. \text{Minimal Inhibitory Concentrations (MICs) Assay} \]

The antibacterial activity of the drug against \textit{Staphylococcus aureus}, \textit{Pseudomonas aeruginosa}, and \textit{Escherichia coli} were determined by the usual twofold dilution technique with Mueller-Hinton agar (Merck Millipore, Darmstadt, Germany) and an inoculum size of 104 cells per mL according to the guidelines of standard procedures. Strains were grown in TSB or LB broth to a turbidity of 0.5 McFarland standards and, using sterile cotton swabs, the bacterial inoculum were added into tubes by lawn culture. Drug serial dilutions were carefully loaded onto the tubes. Tetracycline antibiotic was included as an antibiotic control. All tubes were incubated at 37 °C for 24 h until visible growth was observed and the optical densities were measured and compared with the control antibiotic. The experiment was performed in duplicate. 3.5. \text{Cell Lines and Culture} \]

LNCaP, A549, HepG2, and DBTRG were obtained from ATCC (American Type Culture Collection, Manassas, VA, USA). LNCaP, and A549, were maintained with RPMI 1640 medium containing 10% fetal bovine serum, 100 U/mL penicillin, 100 U/mL streptomycin, 1% sodium pyruvate, and 1% HEPES. DBTRG was maintained with DMEM medium containing 10% fetal bovine serum, 100 U/mL penicillin, 100 U/mL streptomycin, 1% sodium pyruvate, and 1% sodium bicarbonate. All of the cells were at 37 °C in a humidified atmosphere with 5% CO2. All cultures were free of Mycoplasma.
3.6. MTT Assay for Cancer Cell Lines (Growth Inhibition Assay)

The viability of the cells after treatment with various chemicals was evaluated using an MTT assay preformed in triplicate. The cancer cells (5 × 10^3) were incubated in 96-well plates containing 200 μL of serum-containing medium. Cells were permitted to adhere for 12–18 h. Solutions were always prepared fresh by dissolving 0.2% DMSO or drugs in culture medium and added to cancer cells. After 24 h and 48 h of exposure, the drug-containing medium was removed. The cells in each well were then incubated in culture medium with 500 μg/mL MTT for 1 h. Absorbance at 595 nm of the maximum, was detected by an ELISA Reader (Bio-Rad, Hercules, CA, USA).

4. Conclusions

The antibacterial and antitumor activities of analogue peptides based on cyclic tetramer and trimer were described. The modified peptides showed activity against S. aureus in the range of 60–120 μM (24 h). Especially, benzyl group protected cyclo(Gly-L-Ser-L-Pro-L-Glu) exhibited the strongest activities against antibiotic-resistant S. aureus while no cytotoxicity was observed toward gram negative E coli and P. aer. This study also suggests that the hydrophobic protecting group is a useful technique for improving antibiotic activity without increasing resistance or reducing susceptibility to proteolysis. In addition, benzyl protected CtetPs showed an improved activity against tumor cells compared to those without. The poor efficacy of CtriPs and their low cytotoxicity was disclosed. This is probably due to lack of β-turn (U-ACPs) mimicry, orientation of their side-chain group and/or their chemical stability. The present findings also suggest that the potential of hydrophobic group protected cyclic tetrapeptides should not be overlooked when contemplating the design of both antitumor and antimicrobial properties. Further research may promote the great potential of linear peptide linked β-turn (U-ACPs) mimicry [28] for the development of peptide-based antitumor-antibiotic drugs.

Acknowledgments

We thank Taiwan Ministry of Science and Technology for providing the financial support (MOST 103-2113-M-259-010).

Author Contributions

Conceived and designed the experiments: DFT TWC. Performed the experiments: SC YCL. Analyzed the data: SC YCL TWC. Wrote the paper: DFT.

Supplementary Information

Synthetic methods and spectral data (¹H, ¹³C NMR, IR, MS) for cyclic tetrapeptides and their precursors.

Conflicts of Interest

The authors declare no conflict of interest.
References

1. Zasloff, M. Antimicrobial peptides of multicellular organisms. *Nature* **2002**, *415*, 389–395.

2. Fjell, C.D.; Hiss, J.A.; Hancock, R.E.W.; Schneider, G. Designing antimicrobial peptides: Form follows function. *Nat. Rev. Drug Discov.* **2012**, *11*, 37–51.

3. Harris, F.; Dennison, S.R.; Singh, J.; Phoenix, D.A. On the selectivity and efficacy of defense peptides with respect to cancer cells. *Med. Res. Rev.* **2013**, *33*, 190–234.

4. Craik, D.J.; Fairlie, D.P.; Liras, S.; Price, D. The future of peptide-based drugs. *Chem. Biol. Drug Des.* **2013**, *81*, 136–147.

5. Zhang, L.J.; Falla, T.J. Host defense peptides for use as potential therapeutics. *Curr. Opin. Investig. Drugs* **2009**, *10*, 164–171.

6. Nicolas, P. Multifunctional host defense peptides: Intracellular-targeting antimicrobial peptides. *FEBS J.* **2009**, *276*, 6483–6496.

7. Fernandes, F.C.; Rigden, D.J.; Franco, O.L. Prediction of antimicrobial peptides based on the adaptive neuro-fuzzy inference system application. *Biopolymers* **2012**, *98*, 280–287.

8. Arbor, S.; Marshall, G.R. A virtual library of constrained cyclic tetrapeptides that mimics all four side-chain orientations for over half the reverse turns in the protein data bank. *J. Comput. Aided Mol. Des.* **2009**, *23*, 87–95.

9. Park, S.-C.; Kim, J.-Y.; Lee, J.-K.; Yoo, S.; Kim, H.; Seo, C.H.; Nah, J.-W.; Hahm, K.-S.; Park, Y. Synthetic diastereomeric-antimicrobial peptide: Antibacterial activity against multiple drug resistant clinical isolates. *Biopolymers* **2010**, *96*, 130–136.

10. Marr, A.K.; Gooderham, W.J.; Hancock, R.E.W. Antibacterial peptides for therapeutic use: Obstacles and realistic outlook. *Curr. Opin. Pharmacol.* **2006**, *6*, 468–472.

11. Fernandez-Lopez, S.; Kim, H.-S.; Choi, E.C.; Delgado, M.; Granja, J.R.; Khasanov, A.; Kraehenbuehl, K.; Long, G.; Weinberger, D.A.; Wilcoxen, K.M.; *et al.* Antibacterial agents based on the cyclic D,L-α-peptide architecture. *Nature* **2001**, *412*, 452–455.

12. Dartois, V.; Sanchez-Quesada, J.; Cabezas, E.; Chi, E.; Dubbelde, C.; Dunn, C.; Granja, J.; Gritzen, C.; Weinberger, D.; Ghadiri, M.R.; *et al.* Systemic antibacterial activity of novel synthetic cyclic peptides. *Antimicrob. Agents Chemother.* **2005**, *49*, 3302–3310.

13. Torfoss, V.; Isaksson, J.; Ausbacher, D.; Bransdal, B.-O.; Flaten, G.E.; Anderssen, T.; Cavalcanti-Jacobsen Cde, A.; Havelkova, M.; Nguyen, L.T.; Vogele, H.J.; *et al.* Improved anticancer potency by head-to-tail cyclization of short cationic anticancer peptides containing a lipophilic β2,2-amino acid. *J. Pept. Sci.* **2012**, *18*, 609–619.

14. Lian, W.; Upadhaya, P.; Rhodes, C.A.; Liu, Y.; Pei, D. Screening bicyclic peptide libraries for protein-protein interaction inhibitors: Discovery of a tumor necrosis factor-α antagonist. *J. Am. Chem. Soc.* **2013**, *135*, 11990–11995.

15. Lian, W.; Jiang, B.; Qian, Z.; Pei, D. Cell-permeable bicyclic peptide inhibitors against intracellular proteins. *J. Am. Chem. Soc.* **2014**, *136*, 9830–9833.

16. Polcyn, P.; Jurczak, M.; Rajnisz, A.; Solecza, J.; Urbanczyk-Lipkowska, Z. Design of antimicrobialy active small amphiphilic peptide dendrimers. *Molecules* **2009**, *14*, 3881–3905.
17. Janiszewska, J.; Swieten, J.; Lipkowski, A.W.; Urbanczyk-Lipkowska, Z. Low molecular mass peptide dendrimers that express antimicrobial properties. *Bioorganic Med. Chem.* 2003, 13, 3711–3713.

18. Santos, S.; Torcato, I.; Castanho, M.A. Biomedical applications of dipeptides and tripeptides. *Biopolymers* 2012, 98, 288–293.

19. Chakraborty, S.; Tyagi, P.; Tai, D.F.; Lee, G.H.; Peng, S.H. A lead(II) 3D coordination polymer based on a marine cyclic peptide motif. *Molecules* 2013, 18, 4972–4985.

20. Aracil, J.M.; Badre, A.; Fadli, M.; Jeanty, G.; Banaigs, B.; Francisco, C.; Lafargue, F.; Heitz, A.; Aumelas, A. Nouveaux cyclotétrapeptides isolés de l’ascidie cystodyte delle chiaie. *Tetrahedron Lett.* 1991, 32, 2609–2612.

21. Kawagishi, H.; Somoto, A.; Kuranari, J.; Kimura, A.; Chiba, S. A novel cyclotetrapeptide produced by *Lactobacillus helveticus* as a tyrosinase inhibitor. *Tetrahedron Lett.* 1993, 34, 3439–3440.

22. Kawai, M.; Jasensky, R.D.; Rich, D.H. Conformational analysis by NMR spectrometry of the highly substituted cyclic tetrapeptides, chlamydocin and Ala4-chlamydocin. Evidence for a unique amide bond sequence in dimethyl sulfoxide-d6. *J. Am. Chem. Soc.* 1983, 105, 4456–4462.

23. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. *J. Biol. Chem.* 1993, 268, 22429–22435.

24. Singh, S.B.; Zink, D.L.; Polishook, J.D.; Dombrowski, A.W.; Darkin-Rattray, S.J.; Schamtz, D.M.; Goetz, M.A. Apicidins: Novel cyclic tetrapeptides as coccidiostats and antimalarial agents from *Fusarium pallidoroseum*. *Tetrahedron Lett.* 1996, 37, 8077–8080.

25. Scott, R.W.; DeGrado, W.F.; Tew, G.N. De novo designed synthetic mimics of antimicrobial peptides. *Curr. Opin. Biotech.* 2008, 19, 620–627.

26. Thaker, H.D.; Som, A.; Ayaz, F.; Lui, D.; Pan, W.; Scott, R.W.; Anguita, J.; Tew, G.N. Synthetic mimics of antimicrobial peptides with immunomodulatory responses. *J. Am. Chem. Soc.* 2012, 134, 11088–11091.

27. Duggan, P.J.; Lewis, R.J.; Lok, Y.P.; Lumsden, N.G.; Tuck, K.L.; Yang, A. Low molecular weight non-peptide mimics of ω-conotoxin GVIA. *Bioorganic Med. Chem. Lett.* 2009, 19, 2763–2765.

28. Ling, L.L.; Schneider, T.; Peoples, A.J.; Spoering, A.L.; Engels, I.; Conlon, B.P.; Mueller, A.; Schaberle, T.F.; Hughes, D.E.; Epstein, S.; et al. A new antibiotic kills pathogens without detectable resistance. *Nature* 2015, 517, 455–459.

29. Somogyi, L.; Haberhauer, G.; Rebek, J. Improved synthesis of functionalized molecular platforms related to marine cyclopeptides. *Tetrahedron* 2001, 57, 1699–1708.

30. Dube, H.; Durola, F.; Ajami, D.; Rebek, J. Molecular switching in nanospaces. *J. Chin. Chem. Soc.* 2010, 57, 595–603.

31. Mitova, M.; Popov, S.; de Rosa, S. Cyclic peptides from a *Ruegeria* strain of bacteria associated with the sponge *Suberites domuncula*. *J. Nat. Prod.* 2004, 67, 1178–1181.

32. Lim, H.A.; Kang, C.; Chia, C.S.B. Solid-phase synthesis and NMR structural studies of the marine antibacterial cyclic tetrapeptide: Cyclo[GSPE]. *Int. J. Pept. Res. Ther.* 2010, 16, 145–152.

33. Lim, H.A.; Tan, L.T.; Chia, C.S.B. Exploring solution-phase cyclization and sulfamyl safety-catch resin strategies for the total synthesis of the marine antimicrobial cyclic tetrapeptide cyclo(GSPE). *Int. J. Pept. Res. Ther.* 2013, 19, 25–31.
34. Schwalbe, R.; Steele-Moore, L.; Goodwin, A.C. Antimicrobial Susceptibility Testing Protocols; CRC Press: Boca Raton, FL, USA, 2007.
35. Torfoss, V.; Ausbacher, D.; Cavalcanti-Jacobsen, C.dA.; Hansen, T.; Brandsdal, B.-O.; Havelkova, M.; Strom, M.B. Synthesis of anticancer heptapeptides containing a unique lipophilic $\beta^{2,2}$-amino acid building block. *J. Pept. Sci.* **2012**, *18*, 170–176.
36. Held-Kuznetsov, V.; Rotem, S.; Assaraf, Y.G.; Mor, A. Host-defense peptide mimicry for novel antitumor agents. *FASEB J.* **2009**, *23*, 4299–4307.
37. Steinstraesser, L.; Schubert, C.; Hauk, J.; Becerikli, M.; Stricker, I.; Koeller, M.; Hatt, H.; von Duering, M.; Shai, Y.; Steinau, H.-U.; et al. Oncolytic designer host defense peptide suppresses growth of human liposarcoma. *Int. J. Cancer* **2011**, *128*, 2994–3004.
38. Tai, D.-F.; Lin, Y.-F. Molecularly imprinted cavities template the macrocyclization of tetrapeptides. *Chem. Commun.* **2008**, *43*, 5598–5600.
39. Lin, Y.-F.; Lee, S.-M.; Chen, C.-T.; Lu, K.-H.; Tai, D.-F. On-surface cyclization of tetrapeptides using molecularly imprinted polymers as non-covalent auxiliaries. *J. Chin. Chem. Soc.* **2009**, *56*, 127–134.
40. Schweizer, F. Cationic amphiphilic peptides with cancer-selective toxicity. *Eur. J. Pharmacol.* **2009**, *625*, 190–194.
41. Yeung, A.T.Y.; Gellatly, S.L.; Hancock, R.E.W. Multifunctional cationic host defence peptides and their clinical applications. *Cell. Mol. Life Sci.* **2011**, *68*, 2161–2176.
42. Kacprzyk, L.; Rydengard, V.; Morgelin, M.; Davoudi, M.; Pasupuleti, M.; Malmsten, M.; Schmidtchen, A. Antimicrobial activity of histidine-rich peptides is dependent on acidic conditions. *Biochim. Biophys. Acta Biomembr.* **2007**, *1768*, 2667–2680.
43. Mason, A.J.; Moussaoui, W.; Abdelrahman, T.; Boukhari, A.; Bertani, P.; Marquette, A.; Shooshtarizadeh, P.; Moulay, G.; Boehm, N.; Guerold, B.; et al. Structural determinants of antimicrobial and antiplasmodial activity and selectivity in histidine-rich amphipathic cationic peptides. *J. Biol. Chem.* **2009**, *284*, 119–133.
44. Stefanucci, A.; Pinnen, F.; Feliciani, F.; Cacciatore, I.; Lucente, G.; Mollica, A. Conformationally Constrained Histidines in the Design of Peptidomimetics: Strategies for the $\chi$-Space Control. *Int. J. Mol. Sci.* **2011**, *12*, 2853–2890.
45. Bose, A.K.; Strube, R.E. Some derivatives of aspartic and glutamic acids. *J. Pharm. Sci.* **1963**, *9*, 847–851.
46. Miyazawa, T.; Ogura, M.; Nakajo, S.; Yamada, T. Synthesis of monoesters of N-protected $\alpha$-aminocarboxylic acids via the microbial protease-catalyzed regioselective hydrolysis of their diesters. *Biotechnol. Tech.* **1998**, *12*, 431–434.
47. Cheng, C.-T.; Lo, V.; Chen, J.; Chen, W.-C.; Lin, C.-Y.; Lin, H.-C.; Yang, C.-H.; Sheh, L. Synthesis and DNA nicking studies of a novel cyclic peptide: Cyclo[Lys-Trp-Lys-Ahx-]. *Bioorganic Med. Chem.* **2001**, *9*, 1493–1948.
48. Makovitzki, A.; Baram, J.; Shai, Y. Antimicrobial lipopolypeptides composed of palmitoyl di- and tricationic peptides: *In vitro* and *in vivo* activities, self-assembly to nanostructures, and a plausible mode of action. *Biochemistry* **2008**, *47*, 10630–10636.
49. Chakraborty, S.; Lin, S.-H.; Shiuang, D.; Tai, D.-F. Syntheses of Some $\alpha$-Cyclic Tripeptides as Potential Inhibitors for HMG-CoA Reductase. *Amino Acids* **2015**, *47*, doi:10.1007/s00726-015-1977-2.
50. Druyan, M.E.; Coulter, C.L.; Walter, R.; Kartha, G.; Arnbady, G.K. Structure and conformation of cyclo(tri-L-prolyl) in the crystalline state. *J. Am. Chem. Soc.* **1976**, *98*, 5496–5502.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).